How incretin-based therapies address the spectrum of physiologic disturbance in type 2 diabetes

Internet Journal of Academic Physician Assistants

Volumn 8, Issue 1, 2010, Pages

  Deter, D M ^a  

^a Southwest Endocrine Consultants ^*  (United States)

Author keywords

HbA1c; Hypoglycemia; Incretin; Type 2 diabetes; Weight

Indexed keywords

EID: 78649338565     PISSN: 10924078     EISSN: 10924078     Source Type: Journal    
DOI: None     Document Type: Article

References (103)

1. Centers for Disease Control and Prevention: National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2008.
2. American Diabetes Association: Standards of Medical Care in Diabetes 2008. Diabetes Care; 2008; 31(Suppl1): S12-54.
3. Hoerger T, Segel J, et al: Is glycemic control improving in US adults? Diabetes Care; 2008; 31: 81-86
4. Turner R, Cull C, Frighi V, et al: The UK Prospective Diabetes Study Group: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA; 1999; 281: 2005-2012.
5. Carver C: Insulin treatment and the problem of weight gain in type 2 diabetes. Diabetes Educ; 2006; 32: 910-917.
6. Korytkowski M: When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord; 2002; 26(Suppl. 3): S18-S24.
7. Aylwin S, Al-Zaman Y: Emerging concepts in the medical and surgical treatment of obesity. Front Horm Res; 2008; 36: 229-259.
8. The Look AHEAD Research Group: Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes. Diabetes Care; 2007; 30(6): 1374-1383.
9. Nauck M, Homberger E, Siegel EG, et al: Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab; 1986; 63: 492-498.
10. Nauck M, Stockmann F, Ebert R, Creutzfeldt W: Reduced incretin effect in type 2 (non-insulin dependent) diabetes. Diabetologia; 1986; 29(1): 46-52.
11. Edwards C, Todd J, Mahmoudi M, et al: Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans:tudies with the antagonist exendin 9-39. Diabetes; 1999; 48: 86-93.
12. Fehmann H, Hering B, Wolf M, et al: Effects of glucagon-like peptide-I (GLP-I) on hormone secretion from isolated human pancreatic islets. Pancreas; 1995; 11: 196-200.
13. Nauck M, Kleine N, Orskov C, et al: Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia; 1993; 36: 741-744.
14. Orskov C, Holst J, Nielsen O: Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum and non-antraltomach. Endocrinology; 1988; 123(4): 2009-2013.
15. Flint A, Raben A, Astrup A, Holst JJ: Glucagon-like peptide 1 promotes satiety anduppresses energy intake in humans. J Clin Invest; 1998; 101: 515-520.
16. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA: Gastric emptying, glucose response, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab; 1996; 81(1): 327-332.
17. Nauck M, Niedereichholz U, Ettler R, et al: Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol; 1997; 273(5 part 1): E981-988.
18. Stoffers DA, Kieffer TJ, Hussain MA, Drucker DJ, Bonner-Weir S, Habener JF, Egan JM: Insulinitropic glucagon-like peptide 1 agoniststimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas Diabetes; 2000; 49(5): 741-748
19. Zhou J, Wang X, Pineyro MA, Egan JM: Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes; 1999; 49(12): 2358-2366.
20. Toft-Nielsen M, Damholt M, Madsbad S, et al: Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab; 2001; 86: 3717-3723.
21. Vilsbøll T, Krarup T, Deacon C, et al: Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes; 2001; 50(3): 609-613.
22. Vilsbøll T, Brock B, Perrild H, et al: Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulinecretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med; 2008; 25(2): 152-156.
23. Ahren B. Exenatide: a novel treatment for type 2 diabetes. Therapy. 2005;2(2):207-222.
24. Kolterman O, Kim D, Shen L, et al: Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am Health Syst Pharm; 2005; 62: 173-181.
25. DeFronzo R, Ratner R, Han J, et al: Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care; 2005; 28: 1092-1100.
26. Buse J, Henry R, Jan J, et al: Effects of exenatide (exendin-4) on glycemic control over 30 weeks inulfonylurea-treated patients with type 2 diabetes. Diabetes Care; 2004; 27: 2628-2635.
27. Kendall D, Riddle M, Rosenstock J, et al: effects of exenatide (Exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and aulfonylurea. Diabetes Care; 2005; 28(5): 1083-1091.
28. Zinman B, Hoogwerf B, Duran Garcia S, et al. The effect of adding exenatide to a thiazolidinedione inuboptimally controlled type 2 diabetes. Ann Intern Med; 2007; 146: 477-485.
29. Ratner R, Maggs D, Nielsen L, et al: Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab; 2006; 8: 419-428.
30. Blonde L, Klein E, Han J, et al: Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab; 2006; 8: 436-447.
31. Trautmann M, Johns D, Burger J, et al: Change in HbA1c, fastingerum glucose, weight, lipids, and vitaligns by baseline BMI in 2 clinical trials of exenatide vs. insulin comparators. 44th Annual Meeting of the European Association for the Study of Diabetes, September 7-11, 2008. Rome, Italy. Presentation 875. Diabetologia; 2008; 51 (Suppl. 1): XXXXX
32. Buse J, Klonoff D, Nielsen L, et al: Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther; 2007; 29: 139-153.
33. Klonoff D, Buse J, Nielsen L, et al: Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin; 2008; 24(1): 275-286.
34. EMEA 2006: Scientific discussion on Exenatide http://www.emea.europa.eu/humandocs/PDFs/EPAR/byetta/H-698-en6.pdf
35. Byetta Fact Sheet Safety Update: http://www.byettahcp.com/pdf/BYETTA_Fact_Sheet_Safety_Update.pdf
36. Nauck M, Duran S, Kim D, et al: A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who wereuboptimally controlled withulfonylurea and metformin: a non-inferioritytudy. Diabetologia; 2007; 50(2): 259-267.
37. Malone J, Brodows R, Qu Y, et al: Exenatide and biphasic insulin aspart differentially affect postprandial glucose excursions in patients with type 2 diabetes. Diabetologia; 2008; 51(Suppl. 1): S349.
38. Heine R, Van Gaal L, Johns D, et al: Exenatide versus insulin glargine in patients withuboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med; 2005; 143: 559-569.
39. Couto F, Minn A, Pise-Masison C, et al: Exenatide blocks JAK1-STAT1 in pancreatic beta cells. Metabolism; 2007; 56(7): 915-918.
40. Chen J, Couto F, Minn A, Shalev A: Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein. Biochem Biophys Res Commun; 2006; 346(3): 1067-1074.
41. Fehse F, Trautmann M, Holst JJ, Halseth AE, Nanayakkara N, Nielsen LL, Fineman MS, Kim DD, Nauck MA: Exenatide augments first- andecond-phase insulinecretion in response to intravenous glucose inubjects with type 2 diabetes. J Clin Endocrinol Metab; 2005; 90(11): 5991-5997.
42. Kim D, MacConell L, Zhuang D, et al: Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight inubjects with type 2 diabetes. Diabetes Care; 2007; 30: 1487-1493.
43. Drucker D, Buse J, Taylor K, et al: Exenatide once weekly results inignificantly greater improvements in glycemic control compared to exenatide twice daily in patients with type 2 diabetes. Diabetes; 2008; 57(Suppl. 1): A33.
44. Kim T, Boye K, Wintle M, et al: Improved diabetes treatmentatisfaction and weight-related quality of life with both exenatide once weekly and twice daily. Diabetes; 2008; 57(Suppl. 1): A147.
45. Best J, Rubin R, Zhuang D, et al: Higher diabetes treatmentatisfaction associated with improved glucose control for both exenatide once weekly and twice daily. Diabetes; 2008; 57(Suppl. 1): A520.
46. Elbrond B, Jakobsen G, Larsen S, et al: Pharmacokinetics, pharmacodynamics,afety, and tolerability of aingle-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy maleubjects. Diabetes Care; 2002; 25: 1398-1404.
47. Garber A, Henry R, Ratner R, et al: Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet; 2009; 373(9662): 473-481.
48. Nauck MA, Frid A, Hermansen K, et al: Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met). Diabetes Care; 2009; 32; 84-90.
49. Marre M, Shaw J, Brandle M, et al: Liraglutide, a once-daily human GLP-1 analogue, added to aulphonylurea over 26 produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo inubjects with type 2 diabetes (LEAD-1 SU). Diabetic Med; 2009; 26: 268-278.
50. Zinman B, Gerich J, Buse J, et al: Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care; 2009; 32: 1224-1230.
51. Russell-Jones D, Vaag A, Schmitz O, et al: Liraglutide vs insulin glargine and placebo in combination with metformin and sulphonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5 met+SU). Diabetologia; 2009; 52: 4026-4055.
52. Vaag A. Nauck M, Brandle M, et al: Liraglutide, a human GLP-1 analogue, substantially reduces HbA1c in subjects with type 2 diabetes, irrespective of HbA1c at baseline. Diabetologia; 2008; 51(Suppl 1): S68.
53. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S: Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab; 2007; 9(2): 166-174.
54. Buse J, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett J, Zychma M, Blonde L for the LEAD 6tudy group: Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet; 2009; 374(9683): 39-47.
55. Schmitz O, Russell-Jones D, Shaw J, et al. Liraglutide, a human GLP-1 analogue, reduced bodyweight inubjects with type 2 diabetes, irrespective of body mass index at baseline. Diabetologia; 2008; 51(Suppl 1): S354.
56. Vilsbøll T, Zdravkovic M, Le-Thi T, et al: Liraglutide, a long-acting human GLP 1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes mellitus. Diabetes Care; 2007; 30: 1608-1610.
57. Matthews D, Marre M, Le Thi TD, et al: Liraglutide, a human GLP-1 analogue, significantly improves beta cell function in subjects with type 2 diabetes. Diabetologia; 2009; 51(Suppl. 1): S356.
58. Degn K, Juhl C, Sturis J, et al: One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes; 2004; 53: 1187-1194.
59. Prazak R, Rütti S, Ellingsgaard H, et al: Liraglutide induces beta cell proliferation and protects from interleukin-1-beta induced beta cell apoptosis in human islets. Diabetologia; 2008; 51(Suppl. 1): S212.
60. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE; Sitagliptin 036 Study Group: Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care; 2007; 30(8): 1979-1987.
61. Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, Amatruda JM, Langdon RB, Stein PP, Alba M: Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin; 2008; 24(2): 537-550.
62. Chen R., Pfutzner A., Jadzinsky M., Paz-Pacheco E., Xu Z., Allen E. Initial combination therapy with saxagliptin and metformin improves glycaemic control compared with either monotherapy alone in drug-naïve patients with type 2 diabetes. Diabetologia; 2008; 51(Suppl.1): S38.
63. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H: Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia; 2006; 49(11): 2564-2571.
64. Aschner P, Kipnes M, Lunceford J, et al: Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care; 2006; 29: 2632-2637.
65. Nauck MA, Meininger G, Sheng D, et al: Sitagliptin Study 024 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab; 2007; 9: 194-205.
66. Amori R, Lau J, Pittas A: Efficacy and safety of incretin therapy in type 2 diabetes. Systematic review and meta-analysis. JAMA; 2007; 298(2): 194-206.
67. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S: Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diabetes Res Clin Pract; 2007; 76(1): 132-138.
68. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A: Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care; 2007; 30(2): 217-223.
69. Charbonnel B, Karasik A, Liu J, et al: Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care; 2006; 29: 2638-2643.
70. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ: Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care; 2007; 30(4): 890-895.
71. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P; Sitagliptin Study 035 Group: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab; 2007; 9(5): 733-745.
72. Rosenstock J, Brazg R, Andrynk PJ, et al: Sitagliptin Study 019 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther; 2006; 28: 1556-1568.
73. Rosenstock J, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S: Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab; 2007; 9(2): 175-185.
74. Herman G, Stevens C, van Dyck K, et al: Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies withingle oral doses. Clin Pharmacol Ther; 2005; 78: 675-688.
75. Herman G, Bergman A, Stevens C, et al: Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab; 2006; 91: 4612-4619.
76. Rosenstock J, Foley J, Rendell M, et al: Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia inubjects with impaired glucose tolerance. Diabetes Care; 2008; 31(1): 30-35.
77. He Y, Serra D, Wang Y, et al. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet; 2007; 46(7): 577-588.
78. Ahren B, Pacini G, Foley JE, Schweizer A: Improved beta-cell function and insulin sensitivity by the dipeptidyl peptidase IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes. Diabetes Care; 2005; 28: 1936-1940.
79. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D: Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res; 2006; 38: 423-428.
80. Dejager S, Lebeaut A, Couturier A, Schweizer A: Sustained reduction in HbA1c during one-year treatment with vildagliptin in patients with type 2 diabetes (T2DM). Diabetes; 2006; 55(Suppl 1): A29.
81. Rosenstock J, Baron MA, Schweizer A, Mills D, Dejager S: Vildagliptin is as effective as rosiglitazone in lowering HbA1c but without weight gain in drug-naive patients with type 2 diabetes (T2DM). Diabetes; 2006; 55(Suppl 1): A133.
82. Garber A, Camisasca RP, Ehrsam E, Collober-Maugeais C, Rochotte E, Lebeaut A: Vildagliptin added to metformin improves glycemic control and may mitigate metformin-induced GI side effects in patients with type 2 diabetes (T2DM). Diabetes; 2006; 55(Suppl 1): A29.
83. Aschner P, Kipnes M, Lunceford J, Mickel C, Davies M, Williams-Herman D: Sitagliptin monotherapy improved glycemic control in the fasting and postprandialtates and beta-cell function adter 24 weeks in patients with type 2 diabetes (T2DM). Diabetes; 2006; 55(Suppl 1): A462.
84. Karasik A, Charbonell B, Liu J, Wu M, Meehan A, Meininger G: Sitagliptin added to ongoing metformin therapy enhanced glycemic control and beta-cell function in patients with type 2 diabetes. Diabetes; 2006; 55(Suppl 1): A119-120.
85. Rosenstock J, Brazg R, Andryuk PJ, McCrary Sisk C, Lu K, Stein P: Addition of sitagliptin to pioglitazone improved glycemic control with neutral weight effect over 24 weeks in inadequately controlled type 2 diabetes (T2DM). Diabetes; 2006; 55(Suppl): A132-133.
86. Rosenstock J., Aguilar-Salinas C., Klein E., List J., Blauwet M. B., Chen R: (2008a). Once-daily saxagliptin monotherapy improves glycemic control in drug-naïve patients with type 2 diabetes. Diabetes; 2008; 57(Suppl 1): A154
87. Rosenstock J, Sankoh S, List JF: Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naïve patients with type 2 diabetes. Diabetes Obes Metab; 2008; 10(5): 376-386.
88. Nathan D, Buse J, Davidson M et al: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care; 2008; 31: 1-11.
89. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force: American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Management of Diabetes Mellitus 2007. Endocrine Pract; 2007; 13(Suppl 1): May/June.
90. Kothare PA, Soon DK, Linnebjerg H, Park S, Chan C, Yeo A, Lim M, Mace KF, Wise SD: Effect of exenatide on the steady-state pharmacokinetics of digoxin. J Clin Pharmacol; 2005; 45(9): 1032-1037.
91. Kothare PA, Linnebjerg H, Skrivanek Z, Reddy S, Mace K, Pena A, Han J, Fineman M, Mitchell M: Exenatide effects on statin pharmacokinetics and lipid response. Int J Clin Pharmacol Ther; 2007; 45(2): 114-120.
92. Soon D, Kothare PA, Linnebjerg H, Park S, Yuen E, Mace KF, Wise SD: Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men. J Clin Pharmacol; 2006; 46(10): 1179-1187.
93. Exenatide Patient Information: http://pi.lilly.com/us/byetta-pi.pdf
94. Bjørnsdottir I, Olsen A, Larsen U, Helleberg H, Vanggaard J, Oosterhuis B, Van Lier J, Zdravkovic M, Malm-Erjefält M: Metabolism and excretion of the once-daily human GLP-1 analogue liraglutide in healthy subject and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Diabetologia; 2008; 51(Suppl. 1): S356.
95. Flint A, Nazzal K, Jagielski P, et al: Influence of hepatic impairment on pharmacokinetics of the long-acting human glp-1 analogue liraglutide. Diabetes; 2007; 56(Suppl 1): A145.
96. Zdravkovic M, Ekblom M, Brondsted L, Vouis J, Lenneras H, Malm-Erjefalt M: The effect of liraglutide on the absorption pharmacokinetics of concomitant oral drugs with different solubility and permeability properties in healthy subjects. Diabetologia; 2008; 51(Suppl. 1): S355.
97. Januvia prescribing information. http://www.merck.com/product/usa/pi_circulars/j/januvia/januvia_pi.pdf (Accessed 30 Jan, 2009).
98. Pham DQ, Nogid A, Plakogiannis R. Sitagliptin: a novel agent for the management of type 2 diabetes mellitus. Am J Health Syst Pharm. 2008;65(6):521-531.
99. Janumet prescribing information. Retrieved Sept 17, 2009 from Merck & Co. website: http://www.merck.com/product/usa/pi_circulars/j/janumet/janumet_pi.pdf.
100. Onglyza prescribing information. Retrieved September 17th 2009 at:http://packageinserts.bms.com/pi/pi_onglyza.pdf.
101. Onglyza prescribing information. Retrieved September 17th 2009 at:http://packageinserts.bms.com/pi/pi_onglyza.pdf
102. Boulton D., Goyal A., Li L., Kornhauser D. M., Frevert U. (2008). The effects of age and gender on the single-dose pharamcokinetics and saefty of saxagliptin in healthy subjects. 68th Scientific Session of the American Diabetes Association, San Francisco, CA. Abstract 551-P.
103. Bode B, Hale P, Hammer M, et al: Patient reported outcomes in subjects with type 2 diabetes treated with monotherapy regimens of once-daily human GLP-1 analogue liraglutide, or glimepiride. 44th Annual Meeting of the European Association for the Study of Diabetes, September 7-11, 2008. Rome, Italy. (Presentation 894). Diabetologia; 2008; 52(Suppl 1): S357.